VRTX · 10-Q · 2026Q2 · Full report
Product Launch and Transition
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 47 · Surprise 60 · In source text
Vertex is expanding ALYFTREK through regulatory submissions for children aged two to five following positive Phase 3 results. CASGEVY received FDA approval for children aged two and older with SCD or TDT, potentially expanding eligibility to approximately 5,500 patients, while submissions were completed in Saudi Arabia and the United Kingdom for children aged five to eleven. Vertex is preparing for the potential launch of povetacicept in IgAN, with an FDA PDUFA target action date of November 30, 2026, and is advancing additional programs including inaxaplin, zimislecel, VX-017 and suzetrigine.
Key facts
- Expect to complete enrollment in both Phase 3 trials evaluating suzetrigine in diabetic peripheral neuropathy by the end of 2026 source
- Expect to complete full enrollment in the AMPLITUDE Phase 2/3 pivotal trial of inaxaplin in the second half of 2026 source
- Plan to initiate a Phase 1/2 clinical trial to evaluate VX-017 in people with T1D in the near term after FDA cleared IND for VX-017 source
- Completed Phase 2B portion of Phase 2/3 OLYMPUS trial in pMN and confirmed dose selection for Phase 3, which is underway source
- Expect to provide updated timelines for the zimislecel and VX-017 programs in 2026 source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| operating_income | negative | probable | — | Expect to complete full enrollment in the AMPLITUDE Phase 2/3 pivotal trial of inaxaplin in the second half of 2026 |
| operating_income | negative | contingent | — | Plan to initiate a Phase 1/2 clinical trial to evaluate VX-017 in people with T1D in the near term after FDA cleared IND for VX-017 |
| operating_income | negative | probable | — | Completed Phase 2B portion of Phase 2/3 OLYMPUS trial in pMN and confirmed dose selection for Phase 3, which is underway |